How I treat HHV8/KSHV-related diseases in posttransplant patients
نویسندگان
چکیده
منابع مشابه
How I Treat How I treat posttransplant lymphoproliferative disorders
A 19-year-old woman with end-stage renal failure due to congenital kidney disease underwent a living-donor renal transplant in 2006. Eight years later, she was diagnosed with EBV MYC translocation– confirmed BL-PTLD stage IVB (Figure 1) while on treatment with mycophenolate mofetil (MMF), tacrolimus, and low-dose steroids. EBV viral load was very high (5.84 log IU/mL). Due to the aggressive pre...
متن کاملHow I treat How I treat pregnancy-related venous thromboembolism
Venous thromboembolism (VTE) complicates 1 to 2 of 1000 pregnancies, with pulmonary embolism being a leading cause of maternal mortality and deep vein thrombosis an important cause of maternal morbidity, also on the long term. However, a strong evidence base for the management of pregnancy-related VTE is missing. Management is not standardized between physicians, centers, and countries. The man...
متن کاملHow I treat How I treat elderly patients with myeloma
The clinical approach to older patients with myeloma has to be modified to take into account comorbidities and the likelihood of higher treatment-related toxicity. Individualization of management and adequate supportive therapy are important to obtain the best response while minimizing adverse effects. Corticosteroids, novel agents, conventional cytotoxic agents, and high-dose chemotherapy with...
متن کاملHow I Treat How I treat older patients with ALL
3104. 60. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensiveconsolidation for adults with acute lymphoblasticleukemia: cancer and leukemia group B study8811. Blood. 1995;85(8):2025-2037. 61. van Schie RM, Brüggemann RJ, HoogerbruggePM, te Loo DM. Effect of azole antifungal therapyon vincristine toxicity in childhood acutelymp...
متن کاملHow I treat How I treat patients with myelodysplastic syndromes
Critical issues in determining therapeutic strategies for patients with myelodysplastic syndromes (MDSs), who usually die of bone marrow failure with or without conversion to acute myeloid leukemia (AML), include host factors in these mainly older patients, disease heterogeneity, lack of pathogenetic understanding, and a dearth of effective treatments. Even the issue of whether these clonal dis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2012
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2012-04-421412